At Orion Therapeutics, our journey began at the University of Tennessee Graduate School of Medicine (UTGSM), where our founders, Deidra Mountain and Trey Fisher, embarked on a mission to develop an innovative siRNA therapy for vascular disease and restenosis. Along the way, we encountered a common challenge faced by RNA therapeutic and vaccine developers: the critical issue of efficient delivery. This roadblock inspired our dedicated team at UTGSM to pioneer a groundbreaking delivery platform—a versatile system that is agnostic to nucleic acid payloads and allows for precise targeting of previously inaccessible areas of the body.With a steadfast focus on cutting-edge research, patient-centricity, and ethical excellence, Orion Therapeutics is poised to shape the future of medicine. Together, we strive to create a world where every clinical need finds a solution and the promise of RNA therapies becomes a reality for all.